Related Experiment Video
Updated: Mar 14, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions
Maria Grazia Clemente1, Claudia Mandato1, Marco Poeta1
1Maria Grazia Clemente, Pediatric Clinic, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, 07100 Sassari, Italy.
Insights
Non-alcoholic fatty liver disease (NAFLD) in children is a growing concern, often progressing to non-alcoholic steatohepatitis (NASH). Early identification and intervention, including lifestyle changes and potential new therapies, are crucial for managing pediatric NAFLD.
Area of Science:
- Pediatric Gastroenterology and Hepatology
- Metabolic Disorders
- Public Health
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a significant health issue in children, with a 'multiple-hit' model explaining its progression.
- Key factors include insulin resistance (IR), oxidative stress, lifestyle, gut microbiota, and trace element imbalances, contributing to NASH development.
Purpose of the Study:
- To review the pathogenesis, clinical identification, and management strategies for pediatric NAFLD and NASH.
- To highlight the role of clinical parameters, diagnostic tools, and therapeutic interventions.
Main Methods:
- Review of current literature on pediatric NAFLD pathogenesis, diagnosis, and treatment.
- Analysis of clinical and laboratory markers for identifying at-risk children.
- Discussion of diagnostic advancements, including non-invasive imaging techniques.
Main Results:
- Simple clinical and lab parameters aid in identifying children with obesity-related NAFLD and associated risks.
- Liver biopsy remains the gold standard for diagnosis but is invasive; non-invasive methods show promise.
- Lifestyle changes (weight loss, exercise) are primary interventions; pharmacological and surgical options exist for severe cases.
Conclusions:
- Pediatric NAFLD requires early detection and management, integrating lifestyle modifications with emerging therapies.
- Further research into non-invasive diagnostics and targeted treatments for NASH is essential.
Abstract:
Non-alcoholic fatty liver disease (NAFLD) in children is becoming a major health concern. A "multiple-hit" pathogenetic model has been suggested to explain the progressive liver damage that occurs among children with NAFLD. In addition to the accumulation of fat in the liver, insulin resistance (IR) and oxidative stress due to genetic/epigenetic background, unfavorable lifestyles, gut microbiota and gut-liver axis dysfunction, and perturbations of trace element homeostasis have been shown to be critical for disease progression and the development of more severe inflammatory and fibrotic stages [non-alcoholic steatohepatitis (NASH)]. Simple clinical and laboratory parameters, such as age, history, anthropometrical data (BMI and waist circumference percentiles), blood pressure, surrogate clinical markers of IR (acanthosis nigricans), abdominal ultrasounds, and serum transaminases, lipids and glucose/insulin profiles, allow a clinician to identify children with obesity and obesity-related conditions, including NAFLD and cardiovascular and metabolic risks. A liver biopsy (the "imperfect" gold standard) is required for a definitive NAFLD/NASH diagnosis, particularly to exclude other treatable conditions or when advanced liver disease is expected on clinical and laboratory grounds and preferably prior to any controlled trial of pharmacological/surgical treatments. However, a biopsy clearly cannot represent a screening procedure. Advancements in diagnostic serum and imaging tools, especially for the non-invasive differentiation between NAFLD and NASH, have shown promising results, e.g., magnetic resonance elastography. Weight loss and physical activity should be the first option of intervention. Effective pharmacological treatments are still under development; however, drugs targeting IR, oxidative stress, proinflammatory pathways, dyslipidemia, gut microbiota and gut liver axis dysfunction are an option for patients who are unable to comply with the recommended lifestyle changes. When morbid obesity prevails, bariatric surgery should be considered.
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis II: Collaborative Care
Assessment:
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...

